A look at the international race to create human eggs and sperm in the lab
By Rob Stein, Regina G. Barber, Berly McCoy,
NPR [cites CGS' Marcy Darnovsky]
| 11. 29. 2023
In which we meet the pioneers of one of the most exciting — and controversial — fields of biomedical research: in vitro gametogenesis, or IVG.
The goal of IVG is to make unlimited supplies of what Hayashi calls "artificial" eggs and sperm from any cell in the human body. That could let anyone — older, infertile, single, gay, trans — have their own genetically related babies. As such, the field opens up a slew of ethical concerns.
But that isn't stopping researchers from pressing forward.
So, this episode NPR science correspondent Rob Stein gives us a glimpse into the global race to create the first artificial human embryos to see how the competition is unfolding.
Related Articles
The Center for Genetics and Society is delighted to recommend the current edition of GMWatch Review – Number 589. UK-based GMWatch, a long-standing ally, was founded in 1998 by Jonathan Matthews as an independent organization seeking to counter the enormous corporate political power and propaganda of the GMO industry and its supporters. Matthews and Claire Robinson are its directors and managing editors.
CGS works to ensure that social justice, equity, human rights, and democratic governance are front...
By Ryan Cross, Endpoints News | 08.19.2025
Human eggs are incredibly rare cells. The ovary typically produces only 400 mature eggs across a woman’s life. But biologists in George Church’s lab at Harvard University — a group that’s never content with nature’s limits — just got a...
By Katherine Drabiak, Journal of Medical Ethics Forum | 08.07.2025
Adapted from Mitochondrial DNA at
National Human Genome Research Institute
Recently, media outlets around the world have been reporting on children born from pronuclear genome transfer (sometimes called “3-parent IVF,” “mitochondrial donation” or “mitochondrial replacement therapy”) at Newcastle Fertility Center...
By Nicky Hudson, The Conversation | 08.12.2025